FDA approval of Filkri expands Accord’s G-CSF biosimilar portfolio, offering a short-acting option for neutropenia in cancer care.
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more ...
After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin. The FDA has approved Biocon Biologic's Semglee insulin glargine ...
In the second setback this year for etanercept biosimilars, the US District Court for the District of New Jersey has ordered Samsung Bioepis to delay marketing Eticovo until 2029. Samsung Bioepis will ...
FDA's new guidance streamlines biosimilar development, reducing costs and regulatory hurdles and potentially enhancing market access and affordability. The FDA has issued draft guidance that ...
Reforming patent litigation to mirror successful outcomes across Europe could significantly accelerate US biosimilar market entry. The biosimilar market could be accelerated through patent litigation ...
The Center for Biosimilars® looks back at the first year of adalimumab biosimilars on the US market, including every product launch and approval as well as market trends and pricing strategies. Since ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results